Matinas biopharma awarded up to $3.75 million from the cystic fibrosis foundation to support development of oral amikacin (mat2501) for the treatment of ntm infections in cystic fibrosis patients

Bedminster, n.j., nov. 20, 2020 (globe newswire) -- matinas biopharma holdings, inc. (nyse amer: mtnb), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that it has been awarded up to $3.75 million from the cystic fibrosis foundation (cff). the award will support preclinical development of mat2501, matinas' lipid nano-crystal (lnc) oral formulation of the broad-spectrum aminoglycoside amikacin, toward an indication to treat nontuberculous mycobacterial (ntm) lung disease, including infections in patients with cystic fibrosis (cf).
MTNB Ratings Summary
MTNB Quant Ranking